Nutraplus India (BOM:524764) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 30, 2026)


What is Nutraplus India Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Nutraplus India's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

BOM:524764 vs ZTS: Margin of Safety % (DCF Earnings Based) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Nutraplus India's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nutraplus India Margin of Safety % (DCF Earnings Based) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Nutraplus India's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Nutraplus India's Margin of Safety % (DCF Earnings Based) falls into.


Nutraplus India Business Description

Address Subhash Road, 326-A, Pioneer Industrial Estate, Pioneer Eyelets Mfg. Co. Ltd., Jogeshwari (East), Mumbai, MH, IND, 400060
Nutraplus India Ltd is an India based company engaged in manufacturing of active pharmaceutical ingredients (API), intermediates and contract manufacturing of intermediates. It produces bulk drugs, and specialty chemicals and intermediates. The company's product portfolio encompasses therapeutic categories like analgesic, anti-asthma, antimalarial, anti-protozoan infections, mucolyting agent, and antihelmintic.